Anisomycin茴香霉素;Flagecidin;Protein synthesis inhibitor蛋白合成抑制剂;JNK activator JNK激活剂;SP600125;CAS NO:22862-76-6;
货号 | 产品名称 | CAS NO. | 规格 | |
MZ0701-5MG | Anisomycin茴香霉素 | 22862-76-6 | 5mg | |
MZ0701-10MG | Anisomycin茴香霉素 | 22862-76-6 | 10mg | |
MZ0701-50MG | Anisomycin茴香霉素 | 22862-76-6 | 50mg | |
MZ0701-100MG | Anisomycin茴香霉素 | 22862-76-6 | 100mg |
产品描述:
茴香霉素(Anisomycin),来源于灰色链霉菌(Streptomyces griseolus)的吡咯烷抗生素,是一种有效的蛋白合成抑制剂,通过抑制真核生物核糖体的肽酰转移酶活性来发挥作用。据报道能诱导许多细胞的凋亡发生,包括早幼粒细胞白血病细胞、Jurkat细胞、心室肌细胞和结肠腺癌细胞。启动胞内信号和立早基因诱导。
茴香霉素是强效的JNK激活剂,活化MAP激酶(JNK/SAPK和p38/RK)。作为一种有效的信号通路激动剂,选择性引发即刻早期基因诱导的同源性脱敏(c-fos,fosB,c-jun,junB和junD)。茴香霉素(30mg/kg)表现出优于环孢霉素A(MZ2501-10MG)的免疫抑制活性,阻断皮肤移植小鼠的T细胞增殖。
产品特性
化学名:(2R,3S,4S)-2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate | |
CAS NO:22862-76-6 | |
同义名:Flagecidin; Wuningmeisu C; NSC76712; AI350846; 回香霉素; | |
分子式:C14H19NO4 | |
分子量:265.30 g/mol | |
纯度:≥98% | |
外观:白色粉末 | |
溶解性:溶于甲醇、DMSO(≥20mg/ml)、DMF(20mg/ml)
【注】:“≥”表示该化合物大于等于标示浓度,但饱和浓度未知。 |
保存与运输方法
保存:2-8ºC干燥保存,或置于-20ºC长期干燥保存,至少2年有效。
运输:室温运输。
注意事项
(1)本品储存液(溶于有机溶剂,比如DMSO)置于≤-20℃保存(一般情况,-20℃1个月有效;-80℃ 6个月有效,除非有特殊说明),避免反复冻融。任何形式的工作液请现配现用,勿保存再用。
(2)本品对热敏感,易吸潮。保持低温、密封干燥保存。
(3)本品并非商业化的临床药物,仅用作科研用途,不得用作临床诊断或治疗,不得用于食品或药品,绝对禁止用在人身上。
(4) 为了您的安全和健康,请穿实验服并戴一次性手套操作。
储存液配制
质量
溶剂体积 浓度 |
1mg | 5 mg | 10mg |
1mM | 3.7693 mL | 18.8466 mL | 37.6932 mL |
5mM | 0.7539mL | 3.7693 mL | 7.5386 mL |
10mM | 0.3769 mL | 1.8847 mL | 3.7693 mL |
50mM | 0.0754 mL | 0.3769 mL | 0.7539mL |
使用方法【源自文献,仅作参考】
文献1,Yan J et al. c-Jun N-terminal kinase activation contributes to reduced connexin43 and development of atrial arrhythmias. Cardiovasc Res. 2013 Mar 1;97(3):589-97. PMID: 23241357
体外研究(细胞实验): 细胞类型(Cell types):Mouse atrial myocyte line (HL-1) 实验方法(Assay):Atrial myocytes were treated with 50 ng/mL anisomycin with or without 2 µmol/L SP600125, or a corresponding amount of the DMSO solvent for 16 or 24 h followed by biochemical or optical mapping studies. 体内研究(动物模型): 动物模型(Animal Model):Young (6 months) and aged (54 months) male New Zealand White rabbits 实验方法(Assay):LA effective refractory period (AERP) was measured using an S1-S2 pacing protocol and atrial arrhythmias (AT/AF) were induced using burst pacing in open-chest heartsin young rabbits with (n = 4) or without (n = 5)anisomycin treatment (15 mg/kg, iv, four treatments over 9 days)and aged rabbits without anisomycin treatment (n = 6). |
文献2,Lattal KM et al. Behavioral impairments caused by injections of the protein synthesis inhibitor anisomycin after contextual retrieval reverse with time. Proc Natl Acad Sci U S A. 2004 Mar 30; 101(13):4667-72. PMID: 15070775
体内研究(动物模型): 动物模型(Animal Model):Male C57BL/6 mice (8-12 weeks old) 配制方法(Formulation):Anisomycin wasdiluted in salineand dissolved in 1 M HCl. The pH was adjusted to≈7 with 1 M NaOH. 实验方法(Assay):Mice received subcutaneous injections of 50 or 75 mg of anisomycin/kg of body weight or an equivalent volume of saline in the first experiment. Injections in all other experiments were 50 mg/kg of anisomycin or an equivalent volume of saline. |
文献3,Guo Xet al. GSK3β regulates AKT-induced central nervous system axon regeneration via an eIF2Bε-dependent, mTORC1-independent pathway. Elife. 2016 Mar 14;5:e11903.PMID: 26974342.
体内研究(动物模型): 动物模型(Animal Model): 配制方法(Formulation):Anisomycin was dissolved inDMSO to prepare a stock solution anddiluted inPBS before each administration. 实验方法(Assay):Anisomycin (30 mg/kg body weight)or vehicle was injected subcutaneously daily after optic nerve crush. To inhibit OPP incorporation, anisomycin (50 μg/ml) was injected intravitreally 1 hr before and together with OPP administration. |
货号 | 产品名称 | 规格 |
MZ0701-5MG | Anisomycin茴香霉素 | 5mg |
MZ0702-10MG | SP600125 JNK抑制剂 | 10mg |
MZ0201-10MG | Rapamycin (Sirolimus)雷帕霉素(西罗莫司) | 10mg |
MZ2501-10MG | Cyclosporin A (CsA) 环孢霉素A | 10mg |
注意事项
为了您的安全和健康,请穿实验服并戴一次性手套操作。